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ABSTRACT
Proteoglycans located in basement membranes, the thin structures enveloping epithelial and
endothelial layers, are unique in several respects. They are usually large elongated molecules with
a collage of domains that share structural and functional homology with numerous extracellular
matrix proteins, growth factors and surface receptors. They mainly carry heparan sulphate side
chains and these contribute not only in storing and preserving the biological activity of various
heparan sulfate-binding cytokines and growth factors, but also in presenting them in a more “active
configuration” to their cognate receptors. Abnormal expression or deregulated function of these
proteoglycans affect cancer and angiogenesis, and are critical for the evolution of the tumor
microenvironment. This review will focus on the functional roles of the major three heparan
sulphate proteoglycans from basement membranes, perlecan, agrin and collagen XVIII, and their
roles in modulating cancer growth and angiogenesis.

2

Introduction
Basement membrane proteoglycans comprise a selected group of high molecular-weight proteins
which are almost universally decorated with heparan sulfate side chains {2232}. Three main
basement membrane heparan sulfate proteoglycans (HSPGs) have been well characterized. The
first identified HSPG of basement membranes is perlecan, a modular proteoglycan with homology
to growth factors and proteins involved in cell growth, lipid metabolism, adhesion, and homo- and
hetero-typic interactions {1082}. Collagen XVIII is a hybrid collagen/proteoglycan and a member of
the multiplexin gene family together with the closely related collagen XV, which bears chondroitin
sulfate side chains instead of HS chains {2388}. The third HSPG is agrin, an abundant constituent
of most basement membranes with a specialized function at the neuromuscular junction {2208}.
The genes encoding these three HSPGs protein cores are highly conserved and carry disparate
biological functions, from maintenance of basement membrane homeostasis to modulation of
growth factor activity and angiogenesis. Moreover, some of these gene products are expressed in
avascular tissues, such as cartilage, and in musculoskeletal and nervous tissues, where they
modulate neuronal transmission and ocular development. Defects in some of these genes cause
various human inherited disorders and often the disease phenotypes correlate well those of mutant
mice, flies and worms.
An emerging body of work supports the concept that these HSPGs have a dual function as proand anti-angiogenic factors {1779}. Via their N-terminal HS chains, they can stimulate angiogenic
signaling by sequestering (i.e. concentrating) HS-binding growth factors such as FGF2, VEGF and
PDGF, where they present them in a “biologically active” form to their cognate receptors.
Alternatively, via proteolytic processing of their C-termini, these gene products can release
powerful angiostatic fragments such as endostatin and endorepellin, which can act on a paracrine
function on sprouting endothelial cells, either locally or distantly.
This review will focus primarily on these three basement membrane HSPGs and will critically
assess recent information related to their roles in regulating cancer growth and angiogenesis.
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Perlecan, a multimodular and multifunctional proteoglycan
The designation for “perlecan” originates from studies using rotary shadowing electron microscopy
which have shown a tortuous linear polymer with interspersed globular domains resembling a
“string of pearls” {25,137}. Perlecan is a modular HSPG and is one of the largest single-chain
polypeptides found in vertebrate and invertebrate animals {143, 193, 1082}. The five modules of
perlecan are collated from protein units evolutionarily related to molecules involved in cell growth,
lipid uptake and metabolism, intercellular interactions and adhesion (Fig.1). The perlecan’s protein
is ~470 kDa and, together with several O-linked oligosaccharides and as many as four HS chains,
three in domain I and one potential in domain V {812, 1682, 1673}, it can reach a molecular weight
of over 800 kDa.

An intriguing question on perlecan’s evolutionary biology which has been

recently raised {3149} is: What is the advantage of linking 44 different protein modules into a
gigantic polypeptide over the synthesis of individual protomers? Perhaps, the answer lies on the
generation of a protein scaffold, i.e. long heterofunctional protein. The large size of perlecan’s
protein core which spans ~200 nm in length together with the three HS chains, which could span
an additional 6o nm in

three dimension, make perlecan an appropriate linkage between

extracellular matrix and cell surface receptors or complexes of receptors. The various modules of
perlecan and the HS chains have a large repertoire of molecular interactions that include
association with numerous heparin-binding growth factors such as FGF2, VEGF and PDGF {603,
1419, 2934, 1838, 3059, 3060}, and other proteins which are constituents of basement membranes
{2647, 2472}. Perlecan can also be associated with the cell surface {53, 1909} via high-affinity
interactions with integrins, especially α2β1, the main surface receptor for fibrillar collagen {2432}.
Agrin
Collagen XVIII
Basement membrane proteoglycans and angiogenesis
Perlecan binds to many growth factors, and particularly those from the fibroblast growth factor
family, known regulators of neovascularization {3424}. It has been shown that the HS chains are
responsible for the binding to FGF1, 2, 7, 9, 10, 18 {109, 580, 1555, 1610, 1675, 1901} and FGFbinding protein {1707}, and such interactions may lead to enhanced angiogenesis and
chondrogenesis. Most of the research performed on the binding of perlecan to growth factors has
concentrated on FGFs because of the availability of good research tools including recombinant
growth factors and their receptors, antibodies, and the Baf32 cell line that has been transfected
with the genes for the various FGFR isoforms {1675}. The other point about FGFs is that they are
produced by many cell types and in most cases signal cells to proliferate {3412}, although there
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are some notable exceptions, such as FGF9 {3417} and FGF18 {3418, 3419} signaling through
FGFR3 on chondrocytes. This is not caused by an inability of FGF9 to induce cell proliferation
since it is indeed mitogenic when delivered via human chondrocyte perlecan to Baf32 cells
expressing FGFR3c {2928}. These results suggest that FGF bioactivity is strongly influenced by
the contextual environment in which the growth factor is presented, and expand the repertoire of
subtle variations and sometimes paradoxical effects perlecan can display in particular pericellular
environments {2934}.
Perlecan is also involved in the binding and bioactivity of FGF7, also known as keratinocyte
growth factor. Colon carcinoma cells, in which the perlecan gene is disrupted by targeted
homologous recombination, grow slowly, fail to respond to exogenous FGF7 with or without
heparin and are less tumorigenic when injected in immunocompromised mice {1788}. In an
engineered human skin model, perlecan-deficient keratinocytes form a poorly-organized epidermis
which is partially restored by exogenous FGF7 {2798}. Finally, the protein core of perlecan binds to
FGF18, a key factor for chondrogenesis, and alters the mitogenic effect of FGF18 on growth plate
chondrocytes {3221}. This finding is also supported by the similarity in cartilage phenotype
between perlecan null and the FGF18 null mice which both exhibit a defect in endochondral
ossification {2136}.
All of these results need to be confirmed in vivo but support the hypothesis that perlecan is an
inactive sink for FGFs; this would partly explain the reason why cells that are surrounded by
perlecan and produce FGF do not proliferate out of control. Instead, they remain in a quiescent
state unresponsive to many mitogenic signals. Whereas HS chains favor FGF/FGFR interaction,
chondroitin sulfate chains in perlecan could act as “negative” regulators of FGF/FGFR activity,
primarily by physically constraining the FGFs from contacting their cognate receptors. It would be
of interest to determine the structure of the HS attached to the different perlecan species in order
to determine the specific microdomain structures that are responsible for mediating these various
signals.
Perlecan expression correlates with a more aggressive malignant phenotype {172}.Perlecan is
highly expressed in the stroma of various tumors {111, 447}, and is often associated with the
microvasculature which provides nutrients and oxygen to the growing neoplastic cells {2752}. In
1994 we reported the first evidence that perlecan could be involved in angiogenesis. We found that
in tumor xenografts composed of human-derived prostate carcinoma cells and mouse-derived
stromal elements, perlecan secreted by the human prostate cancer cells was deposited along the
newly-formed (angiogenic) vessels of the tumor xenografts {193}. Thus, we hypothesized that
perlecan might directly contribute to the scaffolding of angiogenic blood vessels. Nearly
concurrently, it was demonstrated that perlecan is the major co-factor for the activity of FGF2
{109}, a powerful angiogenic factor {1610}, and for the specific interaction with its cognate receptor
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leading to enhanced mitogenesis and angiogenesis {109}. The key contribution of tumor-derived
perlecan to angiogenesis has been recently confirmed and extended in an epidermal tumor
xenograft model {2383}. Notably, antisense targeting of endogenous perlecan in a variety of
transformed cells including colon carcinoma and melanoma cells causes a significant inhibition of
tumor growth and angiogenesis {837, 1563, 1369}. Ribozyme-mediated knockdown of perlecan
gene expression in metastatic prostate carcinoma cells causes a reduced tumor growth rate,
attenuated vascularization and reduced levels of VEGF {2839}. Seemingly, colon carcinoma cells
with a somatic cell mutation leading to a perlecan null phenotype show growth retardation and
minimal angiogenesis in tumor xenografts {1788}. The central role of perlecan in angiogenesis is
further confirmed by genetic manipulation leading to complete ablation of the perlecan gene {1580,
1585}. In addition to cartilage abnormalities, it was soon realized that perlecan deficiency was
incompatible with adult life due primarily to the failure of blood vessels; most of the embryos die by
day 11.5 of embryonic life due to pericardial hemorrhage, exactly at the time when cardiovascular
circulation starts to fully develop and the intracardiac blood pressure suddenly rises. Moreover, a
significant proportion of perlecan-null mice develop numerous vascular anomalies including
transposition of the great arteries and abnormal coronary arteries {1872, 2078}. In an animal model
expressing a mutated form of perlecan lacking the canonical glycosaminoglycan attachment site,
and thus lacking HS side chains, there is impaired angiogenesis and retarded tumor growth {2337}.
Lack of HS-containing perlecan causes increased intimal hyperplasia and smooth muscle cell
proliferation {2225}, whereas perlecan is required to inhibit thrombosis in an animal model of deep
vascular injury {1647}. A recent study adds a new dimension to these results because it
demonstrates that regulation of perlecan gene expression is regulated by a mechano-transduction
pathway in endothelial cells and that this is a key mechanism through which endothelial cells inhibit
vascular smooth muscle cell proliferation in response to changes in mechanical environment
{3436}.
Recently, a viable mutant animal has been generated in which exon 3 (Hspg2∆3/ ∆3), which
contains two of the three possible HS attachment sites in domain I, has been deleted, thereby
generating a markedly reduced amount of perlecan-attached HS chains {1912}. The mice exhibit
small eyes with degeneration of the lens within 3 weeks of birth, a process accelerated in a double
Col18a1-/- x Hspg2∆3/∆3 mutant background {1912}. Various experimental challenges of these HSdeficient animals result in increased intimal hyperplasia and smooth muscle cell proliferation in
injured arteries {2225}, and impaired angiogenesis and tumor growth {2337}.
A central function for perlecan in cardiovascular development and angiogenesis has been
recently demonstrated in the zebrafish Danio rerio. Morpholino-mediated knockdown targeting
three separate regions of the perlecan mRNA showed relatively normal development of axial
vessels, dorsal aorta and posterior cardinal vein, but a blunted and anomalous development of the
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angiogenic vessels, intersegmental and dorsal longitudinal anastomotic vessels (Figure 2 A,B.)
{3368}. Notably, the perlecan morphant phenotype could be rescued by microinjecting human
perlecan into single-cell embryos. The overall phenotype of the perlecan morphants is similar to
that evoked by null mutations or knockdown of VEGFR2 {2970, 3126}, phospholipase Cγ-1, a
major downstream target of VEGF/VEGFR angiogenic signaling {2975}, receptor blockade by the
small molecule SU5416 {2940}, or by antisense knockdown of VEGF {2913}. Thus, it is possible
that perlecan is required for the proper targeting of VEGF to its cognate receptor during
developmental angiogenesis.
In hepatoblastoma xenografts, VEGF is deposited in the same perivascular pattern as tumorderived perlecan {3283} and the vascular recovery following VEGF blockade by systemic delivery
of

soluble VEGFR1 and VEGFR2 is mediated by enhanced expression of perlecan at such

locations. Concurrently, there is an increase in heparanase in the perivascular zones. Perlecanbound VEGF might be dynamically regulated by heparanase-mediated release from the HS chains
of perlecan {2395} and/or by proteolytic processing of perlecan protein core with ultimate release of
domain I-associated HS/VEGF complexes in a similar way to that shown previously for domain Iassociated FGF complexes {603}. Thus, sequestration and release of perlecan-bound VEGF in the
tumor microenvironment represents a mechanism for continuous vessel growth and tumor
progression. The net result is a protracted activation of VEGFR2 which caused a sustained
activation of the Akt pathway promoting survival and angiogenesis {3283}.
Interestingly, HSPGs can also act across cells or “in trans” {3104}, and specifically can
potentiate in trans VEGFR-mediated angiogenesis {3103}. Arteries and arterioles are surrounded
by mural cells, either vascular smooth muscle cells for large arteries and veins or pericytes for
capillaries. Mural cell HSPGs, most likely including perlecan which is a major product of smooth
muscle cells/pericytes {144}, can transactivate VEGFR2 on endothelial cells by enhancing signal
transduction and by facilitating the formation of receptor-ligand complexes on endothelial cells
{3103}. Thus, perlecan occupies a central role in angiogenesis because it can potentially mediate
not only the VEGF/VEGFR axis but also the transactivation of smooth muscle cells/pericytes during
angiogenesis.
While the overwhelming majority of the reports supports a pro-angiogenic activity of the parent
perlecan proteoglycan, two studies suggest the possibility that perlecan might inhibit tumor growth
and angiogenesis. In human fibrosarcoma {901} and Kaposi sarcoma {1693} cells, antisense
suppression of perlecan increases cell migration and invasion of extracellular matrix, and
stimulates tumor growth.
These apparently contradicting data could be reconciled by considering the fact that perlecan
acts in a cell context-specific manner. In the vast majority of epithelial tumors (i.e., cancers),
perlecan may be required for presenting FGF2 and VEGF to the expanding tumor vasculature,
7

whereas in sarcomas perlecan might be inhibitory via the liberation of cryptic anti-angiogenic
fragments (see next section).
C-terminal portions of basement membrane proteoglycans with angiostatic activity
A general theme is emerging from a vast body of literature. The key concept is that processing of
extracellular matrix proteins, and especially those derived from basement membranes, is a
carefully orchestrated process that can affect either positively or negatively the growth of cells and,
in particular, angiogenesis { 2647,3365, 3150}.
Endostatin─
Cathepsin L, a cysteine protease of the papain superfamily, cleaves collagen XVIII in the hinge
region of the NC1 domain (Fig. 2), thereby liberating endostatin, a strong anti-angiogenic factor
{1705}. Efficient endostatin generation requires a moderately acidic pH, a typical feature of the
tumor microenvironment {705}. Notably, apoptotic endothelial cells secrete cathepsin L which, in
turn, cleaves endorepellin near its C-terminal region thereby liberating endorepellin’s angiostatic
LG3 domain {3422} Thus, cathepsin L and BMP1/Tolloid-like proteases acting in concert could
liberate LG3 from the perlecan associated with the cell surface or embedded within the basement
membrane. Finally, cathepsin L has been recently shown to be a key enzyme required for the
conversion of proheparanase into an active heparanase by specifically cleaving multiple sites
within the linker region {3423}. Thus, differential expression of cathepsin L may have opposite
effects on angiogenesis by generating either anti-angiogenic factors (endostatin and endorepellin’s
LG3) or pro-angiogenic factors (FGF, VEGF, PDGF etc.) via heparanase-mediated cleavage of the
HS chains of perlecan and collagen XVIII. The molecular understanding of this fine balance
between pro- and anti-angiogenic activities will undoubtedly lead to a better treatment of cancer
and other diseases where angiogenesis is predominant.
Endorepellin─The discovery of endorepellin was serendipitous. In a search for novel proteins
interacting with perlecan’s domain V using the yeast two-hybrid system, a clone was identified that
contained the C-terminal portion of collagen XVIII, including endostatin {1914}. It was readily
discovered that perlecan’s domain V blocked HUVEC migration through a collagenous network.
Thus, this fragment was named “endorepellin” to signify its angiostatic function. Endorepellin is
active at nanomolar concentrations in a variety of in vitro and in vivo angiogenic assays {1914}.
The biological interaction between endorepellin, specifically the second globular domain (LG2),
and endostatin is complex and each appears to neutralize the other’s activity {1914}. In mouse
basement membranes endostatin colocalizes with perlecan domain V/endorepellin {1915}. Thus, a
likely function for this protein-protein interaction is a role in basement membrane assembly during
development {2562}. The terminal LG3 domain of endorepellin appears to contain most of its
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angiostatic activity {2221}. Notably, BMP-1/Tolloid-like proteinases cleave endorepellin at a specific
single site, between Asn4196 and Asp4197, thereby generating intact LG3 from the parent molecule
(Fig. 2) {2424}. The sequence around the cleavage site is highly conserved across species, and
mutation of Asp4197 into Ile prevents processing of endorepellin.
During a search for perlecan binding partners using the yeast two-hybrid system and domain V of
perlecan as the bait, we isolated a highly interactive cDNA clone which encoded the NC1 domain
of collagen type XVIII {1914} comprising the powerful anti-angiogenic fragment named endostatin
{1298}. It was soon realized that domain V of the perlecan protein core harbored a powerful
angiostatic activity as demonstrated by various in vitro and in vivo angiogenic assays; this region
was renamed endorepellin to designate its intrinsic anti-endothelial activity {1914}. Endorepellin
interacts specifically with the α2β1 integrin receptor in platelets {2991} and endothelial cells {2221}
and, in the latter, triggers a signaling cascade that leads to disruption of the endothelial actin
cytoskeleton (Figure 2 C-H) and thus to cytostasis {2221, 2647, 2432, 2316}. Using a proteomic
approach, several key proteins involved in angiogenesis including β-actin were significantly downregulated by exposing endothelial cells to recombinant endorepellin {3281}. Importantly, systemic
delivery of human recombinant endorepellin to tumor xenograft-bearing mice causes a marked
suppression of tumor growth and metabolic rate mediated by a sustained down-regulation of the
tumor angiogenic network {2990}. Genetic analysis using siRNA-mediated block of endogenous
α2β1 integrin or animals lacking the α2β1 integrin receptor have definitively shown that this is a
key receptor for endorepellin, and thus for perlecan protein core, and have further demonstrated
that endorepellin targets the tumor xenograft vasculature in an α2β1 integrin-dependent manner
{3219}. Interestingly, endorepellin has been detected as a released product in the upper
proliferating zone of fetal growth plate {3222} suggesting that cartilage endorepellin might
counteract blood vessel invasion in cartilage. The take-home message is that endorepellin might
represent a member of the family of cryptic domains residing within larger parent molecules of the
extracellular microenvironment that act in a dominant negative manner. Other processed
fragments of extracellular matrix proteins have recently been described and shown to interact with
distinct integrin receptors {2719}.
Notably, the last laminin-like globular domain, LG3 (Fig. 2), possesses most of the biological
activity {2221} and can be released from the parent molecule by BMP-1/Tolloid-like
metalloproteinases {2424} which recognize an ND dipeptide which is highly conserved across
species including human, mouse, Drosophila and zebrafish {3368}. This highly-conserved region
within the perlecan protein core together with the high conservation of BMP-1/Tolloid-like
metalloproteinases suggests that liberation of LG3 might be of physiological importance. Mutations
in LG3 producing molecules with lower or no affinity for calcium {2424} disrupt LG3 angiostatic
activity. It is noteworthy that the proximal two globular domains of endorepellin, LG1 and LG2,
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might be occupied by a number of high-affinity ligands such as dystroglycan and endostatin within
basement membranes and on cell surfaces {2432, 2316}. In contrast, LG3 might be relatively
accessible and thus likely to be released by partial proteolysis, a process that is common to most
LG domains of laminin {1784, 2234, 1898}.
Over a decade ago, Oda et al {771} reported the presence of perlecan’s LG3 fragments in the
urine of end-stage renal failure patients . The LG3 fragments had N-terminal residues (i.e., cleaved
by BMP-1/Tolloid-like metalloproteinases) identical to those found in endothelial cells by us.
Following this initial observation, a number of investigators have detected LG3 in several
pathological conditions (Table 1). For instance, similar LG3 fragments have been found elevated in
the urine of patients with chronic allograft nephropathy {2634}, and in the amniotic fluid of pregnant
women {3351} with a marked increase in women with symptoms of premature rupture of fetal
membranes {2098, 2662} and those carrying trisomy 21, Down syndrome, fetuses {3023}. In
addition, endorepellin fragments have been detected in normal human blood {2200}, in the urine of
children with sleep apnea {3437} and in the media conditioned by apoptotic endothelial cells {2231,
2618}. In endothelial cells, the released LG3 interacts with the α2β1 integrin receptor of fibroblasts
and triggers a signaling cascade that leads to activation of an anti-apoptotic pathway and
potentially to a fibrogenic response {2900}. In fibrotic diseases, endothelial cell apoptosis precedes
the recruitment of fibroblasts, and thus release of LG3 could affect not only angiogenesis, but also
the production of collagen and the overall sclerotic response. This is another example of cellspecific context in which cryptic perlecan fragments might exert diverse effects.
LG3 is also found in the secretome of pancreatic and colon carcinoma cells {2864,2424}.
Finally, circulating LG3 levels are reduced in patients with breast cancer suggesting that reduced
titers might be a useful biomarker for cancer progression and invasion. The significance of LG3
appearance in all of these conditions is not clear but a possibility is that LG3 might represent a sign
of vascular injury or a biomarker for the high turnover rate of malignant cells.
We propose that endorepellin/LG3 is liberated via partial proteolysis during tissue remodeling
and cancer growth thereby representing an additional layer of control for angiogenesis, which also
depends on the cellular context and specific integrin expression {2647}. One possibility is that
tumor growth might be enhanced in vivo by a lack of circulating LG3.

Although this is an

unanswered question, recent studies using α2β1 integrin-null mice have reported an increased
angiogenesis in the granulation tissue of wounded animals {2992, 2993}. Tumor angiogenesis is
dependent on the “cancer cell context“ in α2β1 integrin-null animals further corroborating the
importance of cross-talk between the invading cancer cells and the tumor microenvironment
{3333}.
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An endorepellin-like structure in agrin─Agrin harbors an endorepellin-like domain at its Cterminus (Fig. 2). This domain comprises three LG modules interspersed by three EGF-like repeats
{2208}. Notably, endorepellin-like and LG3 fragments are generated from agrin by a specific serine
protease, neurotrypsin {3380}. Neurotrypsin cleaves agrin at two homologous sites liberating a 90kDa fragment and the C-terminal globular domain, LG3 {3380}. The release of cryptic fragments
within agrin could promote interactions with other proteins and receptors that were inaccessible to
full-length agrin {3380}. While there is no evidence that any of these modules affect angiogenesis,
there is ample evidence that they play important biological roles and can also mediate signaling
events propagated from surface receptors. For example, the endorepellin-like region of agrin is
involved in binding to dystroglycan and integrins {3382, 2208}. In addition, the LG3 module of agrin
signals through a synaptic receptor that has been recently identified as the Na+-K+-ATPase {3381}.
Agrin LG3 inhibitory activity evokes membrane depolarization and increases action potential in
neurons by interacting with the α3 subunit of the Na+-K+-ATPase, a member of the family of ion
pumps {3381}. A mini-agrin gene composed of the N-terminus (which binds to laminin γ1) and the
C-terminal endorepellin-like structure (which binds to α-dystroglycan) can function as a biological
linker and can ameliorate muscular dystrophy caused by mutation in the laminin α2 gene {3062}.
Interestingly, chimeric proteins composed of the N-terminus of agrin and the mouse endorepellin
can also have similar linker/stabilizing activity and rescue the dystrophic phenotype {3062}. A
miniaturized form of agrin, consisting of the lamini-binding and MuSK-activating domains, can
restore neuromuscular junction in agrin mutant mice when expressed by developing muscle
{3644}. It is, therefore, possible that LG-containing modules interspersed by EGF-like repeats,
such as those present in perlecan and agrin, could serve unique cell- and tissue-specific functions.
Not surprisingly, these modules have been conserved for over 500 million years of evolution.
Utilization of endorepellin-like structures which bind with high affinity to surface receptors such αdystroglycan and α2β1 integrin might be utilized in the future for the treatment of diseases in which
these two receptors are involved.

A WORKING MODEL OF PERLECAN’S ROLE IN TUMOR ANGIOGENESIS
Extracellular matrix-derived signals control vascular morphogenesis and remodeling {2070, 2717,
3365}. Growth factors such as FGF and VEGF require not only their receptors for full biological
activity, but they also require essential co-factors such as HS and, indirectly, the protein core of
perlecan and other extracellular HSPGs. Thus, perlecan functions in targeting, storage and
delivery of growth factors to their functional receptors. It has been recently proposed that complex
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molecules such as perlecan, which reaches 100–200 nm in length, could serve to cluster various
ectodomains of transmembrane proteins, stabilize their interactions and thus create a stable
“signalosome” {3149}. During tumor progression, the vascular basement membrane undergoes
constant remodeling {2070} and when heparanase is preponderant {2395} it could release growth
factors from the HS chains of perlecan (Figure 4). These increased levels of growth factors
together with the cofactor HS would activate their respective cognate receptors which, in turn,
would activate the pro-survival activity of Akt and ultimately promote angiogenesis and tumor
progression. Obviously, marked proteolysis would also generate a large number of growth factors
and cytokines that are bound to the protein core including PDGF, FGF7, and FGF2. When
proteolysis is somewhat “limited”, endorepellin and LG3 could be liberated in the tumor
microenvironment to counteract the FGF/FGFR and VEGF/VEGFR2 axes: endorepellin interacts
with the α2β1 integrin receptor and triggers a signaling cascade that leads to disruption of the
endothelial cell actin cytoskeleton, inhibition of cell motility, and ultimately inhibition of
angiogenesis and concurrent tumor suppression (Figure 4). This conceptual framework could be
easily applied to other endogenous inhibitors of angiogenesis associated with the basement
membrane, such as collagen XVIII, which is also an HSPG and contains at its C-terminus
endostatin {2946}, and collagen IV which contains tumstatin {2719}.
Understanding the balance between pro- and anti-angiogenic cues would be of great
therapeutic potential in the future. Would blocking heparanase, for instance, be a suitable
treatment for certain forms of highly vascularized cancers? What protease inhibitors would be most
beneficial for tilting the balance toward a less vascularized or avascular condition? Should heparin
mimetics be used in tumor therapy to cause the diffusion of growth factors away from the tumor
cells? Would combination therapy work? These important questions can conceivably be answered
in the near future after we elucidate the role each component exerts in the complex processes of
vascular generation, regression and remodeling that occur during cancer evolution.
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FIGURE LEGENDS
Fig. 1. Structural domains of human perlecan, agrin and collagen XVIII. The five domains of
perlecan are in Roman numerals from the N- to the C-terminus. The other domains of agrin and
collagenXVII are listed or detailed in the text.
Fig. 2. Schematic representation of the C-termini of perlecan, agrin and collagen XVIII (left) and
their respective cognate receptors (right). Also annotated are the locations of various proteases
generating intact modules or fragments thereof from the three polypeptides.
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Location
Urine
Urine
Amniotic fluid

Amniotic fluid

Blood

Secreted by
endothelial cells
Secreted by various
cancer cells
Urine

Condition
End-stage renal
disease
Chronic allograft
nephropathy
Premature rupture
of fetal membranes
Mothers carrying
Down Syndrome
fetuses
Normal subjects
and breast cancer
patients
Endothelial cells
undergoing
apoptosis
Pancreatic and
colon carcinoma
cells
Children with sleep
apnea

Functional Implication
Biomarker for vascular
injury
Biomarker for immunemediated vascular injury
Biomarker for fetal
ischemia and vascular
injury
Biomarker for abnormal
fetal development and
vascular injury
Reduced in breast
cancer patient:s; role as
anti-angiogenic factor
Potential function as a
paracrine inducer of
fibrosis
Potentially linked to the
highly turnover rate of
transformed cells
Potential biomarker of
transient brain ischemia

Reference
{771}
{2634}
{2098, 2662}

{3023}

{3289}

{2231, 2618, 2900}

{2864, 2424}

{3437}

Table 1. Presence of perlecan’s LG3 module in various tissues and biological fluids, and potential
functional implications.
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